Nav: Home

Kansas State University contributes to potential Zika virus vaccine development

October 04, 2016

MANHATTAN, KANSAS -- A research team that includes scientists with Kansas State University's Biosecurity Research Institute has developed a promising Zika virus vaccine.

The vaccine, a DNA vaccine, is safer and more effective against Zika virus and could offer more affordable long-term protection, researchers said.

"This vaccine is a successful advancement in developing control strategies for Zika virus by creating widespread immunity in susceptible populations," said Stephen Higgs, director of the Biosecurity Research Institute. "One shot of DNA vaccine will offer protection for years at a much lower cost, which is especially beneficial for endemic countries in Latin America and Africa."

Higgs is a co-author of the vaccine study, "Rapid development of a DNA vaccine for Zika virus," that appears in the journal Science.

Researchers with the National Institutes of Health led the study, which also involves researchers at the Federal University of Rio de Janeiro, Harvard Medical School, Frederick National Laboratory for Cancer Research, Bioqual and the Walter Reed Army Institute of Research.

Kansas State University scientists in the College of Veterinary Medicine -- including Dana Vanlandingham, assistant professor of virology, and Yan-Jang Huang, postdoctoral fellow in diagnostic medicine and pathobiology -- played a critical role in the study by producing and characterizing viral stocks to determine how the DNA vaccine induced immunogenecity and protection.

DNA vaccines deliver noninfectious DNA materials to stimulate the immune system to produce viral antigens.

The DNA vaccine for Zika virus is more immunogenic and effective than other vaccines because it can create memory responses, which inactivated vaccines with killed viruses fail to produce, Higgs said. The DNA vaccine also is safer because it does not use attenuated viruses to produce viral antigens. Attenuated vaccines contain live microbes, which potentially can cause adverse events or harmful effects.

"We anticipate that this vaccine may have long-term memory immune response as other DNA vaccines also have achieved such a goal," Huang said. "The vaccine is a suitable and ideal tool as an emergency response to the current Zika virus outbreak and could build robust herd immunity."

The research is critical for the control of Zika virus at the preventive stage and at the population level, Vanlandingham said. The critical next step is to initiate safety and efficacy trials in humans.

"The availability of vaccines for Zika virus is more significant than any specific antiviral treatments," Vanlandingham said. "Vaccination normally generates protective immunity that prevents the disease for years in a population at a relatively low cost; whereas, antiviral therapies can only be treating the diseases at a higher cost rather than offer long-term protection."

The research received startup funding from the diagnostic medicine and pathobiology department in the College of Veterinary Medicine. The National Institute of Allergy and Infectious Diseases and the Frederick National Laboratory for Cancer Research also provided funding.

Other Zika virus research at the Biosecurity Research Institute has involved a two-part approach: Researchers are studying mosquitoes to understand how they become infected with Zika virus and researchers are providing the virus to collaborative organizations for further study. Biosecurity Research Institute researchers recently found that Culex mosquitoes do not appear to transmit Zika virus.
Collaborative researchers on the Science publication included Kimberly A. Dowd, Sung-Youl Ko, Kaitlyn M. Morabito, Eun Sung Yang, Rebecca S. Pelc, Christina R. DeMaso, David N. Gordon, John Robert Gallagher, Xuejun Chen, John-Paul Todd, Audray Harris, Martha C. Nason, Mario Roederer, Wing-Pui Kong, John R. Mascola, Theodore C. Pierson and Barney S. Graham, all with the National Institute of Allergy and Infectious Diseases at the National Institutes of Health; Leda R. Castilho, National Institute of Allergy and Infectious Diseases at the National Institutes of Health and the Federal University of Rio de Janeiro; Peter Abbink, Michael Boyd, Ramya Nityanandam and Dan H. Barouch, all with Harvard Medical School; Yaroslav Tsybovsky, Frederick National Laboratory for Cancer Research; Hanne Andersen and Mark G. Lewis, both with Bioqual; and Rafael De La Barrera, Kenneth H. Eckels and Richard G. Jarman, all with the Walter Reed Army Institute of Research.

Kansas State University

Related Vaccines Articles:

Understanding T cell activation could lead to new vaccines
Scientists could be one step closer to developing vaccines against viruses such as Zika, West Nile or HIV, according to Penn State College of Medicine researchers.
Vaccines do work for pandemic flu, says study
Vaccines are successful in preventing pandemic flu and reducing the number of patients hospitalized as a result of the illness, a study led by academics at the University of Nottingham has found.
Research could lead to better vaccines and new antivirals
Scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified a new regulator of the innate immune response -- the immediate, natural immune response to foreign invaders.
Toward opioid vaccines that can help prevent overdose fatalities
In 2014, the number of deaths from opioid overdoses in the US jumped to its highest level on record.
New, more effective strategy for producing flu vaccines
A team of researchers led by Yoshihiro Kawaoka, professor of pathobiological sciences at the University of Wisconsin-Madison School of Veterinary Medicine, has developed technology that could improve the production of vaccines that protect people from influenza B.
A method for storing vaccines at room temperature
Several simple and inexpensive techniques make it possible to store antiviral-vaccines at room temperature for several months.
Engineers design programmable RNA vaccines
MIT engineers have designed programmable RNA vaccines that could be rapidly manufactured and deployed.
Zika vaccines protect mice from infection
A single dose of either of two experimental Zika vaccines fully protected mice challenged with Zika virus four or eight weeks after receiving the inoculations.
Can we hypercharge vaccines?
Researchers at Boston Children's Hospital report that a fatty chemical naturally found in damaged tissues can induce an unexpected kind of immune response, causing immune cells to go into a 'hyperactive' state that is highly effective at rallying infection-fighting T-cells.
Vaccines: Don't leave home without them
While Americans should be fully vaccinated before travelling internationally to avoid infection with highly contagious diseases such as measles and hepatitis A, many are not, suggest two studies being presented at IDWeek 2015™.

Related Vaccines Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".